Neurocrine Biosciences Inc

Insider trading at Neurocrine Biosciences shows steady confidence: executives buy/sell for liquidity but maintain long‑term stakes, keeping volatility low and focusing on future neuro‑psychiatric breakthroughs.

Insider buying surge at Neurocrine shows executive confidence ahead of Phase 2 data; could lift the stock toward its recent high.

Neurocrine CFO’s fresh buy signals insider confidence amid rising stock, highlighting upcoming Phase‑2 data that could boost a biotech rally.

Neurocrine insider Bénévich’s 12,830‑share option exercise signals strong confidence in its pipeline and may boost investor sentiment ahead of earnings.

Neurocrine insider buying: CCO Eric Ben Evi­ch purchases 12,830 shares at $35.99, signaling confidence amid a 52‑week low and potential upside for investors.